Inoperable liver cancer and LENVIMA
A clinical study of LENVIMA showed:
The median* time people treated with LENVIMA were alive was 14 months compared to 12 months for people treated with sorafenib. These results showed that treatment with LENVIMA was noninferior (not unacceptably worse) in comparison to sorafenib
*Median: The middle number in a list of numbers arranged from lowest to highest.
41% (194 out of 478 people) treated with LENVIMA had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 12% (59 out of 476 people) treated with sorafenib
How does LENVIMA work?
Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.